In addition, CD38 serves as a critical initial enzyme in the conversion of NAD+ to ADP-ribose and cyclic ADPR (cADPR), leading to a downstream production of adenosine via the alternative adenosine-generating pathway creating an immune-suppressed tumor microenvironment (TME; 7, 9). This evidence concerns the gene CD38 and neoplasm.